Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Sponsor: Case Western Reserve University
This PHASE4 trial investigates HIV Infection and is currently completed. Case Western Reserve University leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Case Western Reserve University
- Pfizer
- Rush University
- Stanford University
- University of California, San Francisco
- amfAR, The Foundation for AIDS Research
For direct contact, visit the study record on ClinicalTrials.gov .